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Abstract The protein phosphatases PP1c, PP2Ac and PP2CK
are shown to dephosphorylate protein kinase CN (PKCN) in vitro;
of these PP2Ac displayed the highest specific activity towards
PKCN. The role of PP2Ac in the dephosphorylation of PKCN in
cells was supported by the demonstration that these proteins
could be co-immunoprecipitated from NIH3T3 cells. However
the observation that binding of Mg-ATP to PKCN could protect
the enzyme from dephosphorylation by PP2Ac in vitro indicates
that an additional input/factor is required for dephosphorylation
in vivo. ß 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The protein kinase C (PKC) family of lipid-dependent ser-
ine/threonine kinases are known to play key roles in a whole
range of cellular functions, including cell growth, di¡erentia-
tion and apoptosis. To unravel the molecular mechanisms
underlying the diverse roles of the di¡erent members, it is
important to de¢ne how each PKC isoform is regulated. In
this regard much e¡ort has been directed at de¢ning the ef-
fectors involved in receptor-dependent activation. However it
is evident that regulated loss of function, i.e. desensitisation, is
critical in the response of cells. This is exempli¢ed by the
action of the PKC activator bryostatin I which can block
responses to the PKC activator tetradecanoyl phorbol acetate
(TPA), and induces an anomalous biphasic degradation of
PKCN [1]. This demonstrates clearly that the response of cells
is dependent on the timing of PKC activation.
For PKCK, induced degradation appears to require the
tra⁄c of the membrane-associated protein to a perinuclear
region, where dephosphorylation occurs, followed by ubiqui-
tin conjugation and degradation through a proteasomal mech-
anism [2^5]. Evidence on the degradation of PKCN indicates
that this protein also undergoes dephosphorylation prior to a
ubiquitin-dependent degradation [6]. The degradation of PKC
(cPKC and nPKC isotypes) is not only a function of chronic
pharmacological activation, but occurs in response to sus-
tained activation by hormones and growth factors [7,8]. In
particular for PKCN this process is under cell cycle control.
PKCN overexpression induces a cell cycle arrest consistent
with the notion that PKCN degradation may contribute to
cell cycle progression (recently reviewed [9]). However the
mechanisms involved in this are unknown.
The mammalian cell contains four subfamilies of serine/
threonine protein phosphatases, PP1-like, PP2A-like, PP2B
and PP2C, which are responsible for the dephosphorylation
of cellular proteins involved in a whole host of functions such
as the regulation of cell metabolism, DNA replication, cell
cycle control, development and transformation [10]. Both
PP1 and PP2A exist in the cell as a variety of holoenzyme
complexes, and are major phosphatases in the cell [11,12].
Dimeric PP2B, otherwise known as calcineurin, requires
Ca2/calmodulin binding for activation and hence is an im-
portant player in Ca2 signalling [13]. Unlike the above pro-
tein phosphatases, PP2C is a monomeric protein that is char-
acterised by its dependence on Mg2 or Mn2 for activity.
Although the functional roles of mammalian PP2C are not
well de¢ned, it is known to associate with p38 kinase and
inhibit the p38 and JNK stress-activated MAP kinase path-
way [14]. Studies to date analysing the mechanism of dephos-
phorylation of PKC have implicated the role of phospho-ser-
ine/threonine protein phosphatase PP2A. A heterotrimer form
of PP2A was seen to dephosphorylate PKCK in vitro and
inhibitors to PP2A have been shown to induce hyperphos-
phorylated forms of PKCK (and also PKCN and O) [2,3,15,16].
The studies here describe the speci¢city of protein phospha-
tases in vitro towards the dephosphorylation of PKCN. This
indicates that PP2A is likely to play the key role in vivo and
this conclusion is supported by demonstration that PKCN and
PP2A can be co-immunoprecipitated from cells. However the
protective e¡ect of Mg-ATP in vitro implies that there must
be a further regulatory step in initiating dephosphorylation in
vivo.
2. Materials and methods
2.1. In vitro protein phosphatase treatment of PKCN
As described previously [17], baculovirus-expressed PKCN is phos-
phorylated at three regulatory phosphorylation sites (see Section 3).
To assess the dephosphorylation of these sites, baculovirus-expressed
recombinant PKCN (Panvera) was treated with puri¢ed protein phos-
phatases. PP1c and PP2Ac were puri¢ed from rabbit skeletal muscle
[18]. The dimeric (PP2AD) and trimeric (PP2AT55 and PP2AT72) ho-
loenzyme forms with respectively PR55/B and PR72/BP as the third
variable subunit, were also puri¢ed from rabbit skeletal muscle [19].
PP2CK was expressed and puri¢ed as a GST fusion protein from
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bacteria [20]. A total reaction volume of 50 Wl was set up to contain
the following: 20 mM Tris^HCl (pH 7.5), phosphatidylserine (PtdSer)
and TPA (25 Wg PtdSer, 2 WM TPA ¢nal), 8 ng^1 Wg phosphatase (as
indicated), 100^500 ng PKCN recombinant protein; incubations were
carried out at 30‡C. The reactions were stopped by the addition of
4USDS sample bu¡er, boiled and stored in liquid nitrogen. Samples
were separated by SDS^PAGE for subsequent analysis by Western
blotting.
2.2. Western blotting
Protein samples in SDS sample bu¡er were separated on 10% SDS^
PAGE and transferred onto polyvinylidene £uoride (PVDF) mem-
branes (Millipore) using a wet transferring system (Bio-Rad). Mem-
branes were blocked for 1 h at room temperature in PBS bu¡er con-
taining 0.1% Tween 20 and 5% (w/v) skimmed milk powder [21].
When probing for phosphorylation sites, skimmed milk powder was
substituted by 3% BSA. Membranes were incubated with primary
antibody, either anti-PKCN monoclonal (Transduction labs.) or poly-
clonal antiserum (1 in 5000) raised in rabbit against a synthetic pep-
tide [22]. Phosphorylation-speci¢c antisera (1 in 3500) were incubated
in the presence of dephospho-peptide overnight at 4‡C [23]. The mem-
branes were washed, incubated with secondary antibody conjugated
to HRP and cross-reactivity was visualised using an enhanced chem-
iluminescence (ECL) detection system (Amersham Pharmacia). For a
quantitative comparison of protein bands, an exposure of ¢lm within
the linear range was scanned with the Adobe UMAX magic scan, and
relative band intensities calculated using NIH image software.
2.3. Phosphatase activity assays
Protein phosphatase activity was determined either by using phos-
phorylase as a substrate as described in the protein phosphatase assay
system (Life Technologies), or using p-nitrophenylphosphate (pNPP)
as substrate. Using pNPP as substrate, a dilution of the phosphatase
was added to a reaction mixture containing 25 mM Tris (pH 7.5),
2 mM MgCl2 and 10 WM pNPP in a total volume of 1 ml. The
reactions were carried out at room temperature and the optical den-
sity (OD) readings were taken at 420 nm at 30 s intervals.
2.4. Cell culture and transfection
NIH3T3 mouse ¢broblasts were maintained in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) supplemented with penicillin (60 Wg/ml),
streptomycin (100 Wg/ml), and 10% (v/v) foetal calf serum in a 10%
CO2 humidi¢ed incubator at 37‡C. The adherent cells were passaged
three times a week by detaching cells with 0.25% (v/v) trypsin/versene
and seeded at a density of 2U105 cells/ml. Cells (35 mm/100 mm
plates) were transfected using Lipofectamine reagent (Gibco BRL)
with 1^5 Wg of plasmid DNA (myc-PKCN in pEFlink or GFP-
PKCN in pEGFPC3 as indicated) for 6^18 h. Following transfection,
the cells were placed in fresh low serum medium (0.05% FCS) and
incubated for a further 24 h prior to experimentation. Whole cell
extracts were harvested in 4USDS sample bu¡er. Samples were boiled
to 95‡C and stored at 320‡C or in liquid nitrogen (when analysing for
phosphorylation status of proteins) prior to loading on SDS^PAGE.
2.5. Immunoprecipitation
Following a rinse with cold PBS, cells were scraped into 500 Wl lysis
bu¡er (20 mM Tris (pH 7.5), 2 mM EDTA, 0.2 M NaCl, 10 mM
benzamidine, 0.2 mM PMSF, 10 Wg/ml leupeptin, 100 Wg/ml aproti-
nin, 10 WM microcystin LR and 1% Triton X-100 (Sigma and Alexis))
for a 100 mm dish. Samples were snap frozen in liquid nitrogen and
homogenised using a glass Dounce homogeniser. After pre-clearing
insoluble material, the lysate was incubated with 5^10 Wg of antibody,
followed by incubation with protein-G-Sepharose beads (Sigma). The
beads^antibody complex was carefully washed three times in lysis
bu¡er, boiled in SDS sample bu¡er and the immunoprecipitated pro-
teins were subjected to SDS^PAGE. PP2Ac was detected with a
monoclonal antibody to PP2Ac (S. Dilworth, manuscript in prepara-
tion).
3. Results
3.1. Dephosphorylation of PKCN in vitro
In order to assess the intrinsic speci¢city of di¡erent classes
of protein phosphatase towards PKCN, puri¢ed proteins were
tested in vitro. The dephosphorylation of the three critical Ser/
Thr phosphorylation sites occupied in baculovirus-expressed
PKCN (T505, S643, S662) was monitored using site-speci¢c
antibodies. The phosphatase activities were titrated against
PKCN such that similar activities were compared (note the
very di¡erent protein concentrations; see below). As illus-
trated in Fig. 1A^C, the puri¢ed catalytic subunits of PP1
(A), PP2A (B) and PP2C (C) all were able to dephosphorylate
PKCN in vitro. Furthermore none of these phosphatases dis-
played any marked site speci¢city, although in each case the
S643 site, which resides within the sequence
TKPQLS(P)FSDKT was the most rapidly dephosphorylated.
Despite the similar site speci¢city of these three phospha-
tases the speci¢c activities varied greatly. Based upon the ini-
tial rates of dephosphorylation of PKCN determined by scan-
ning densitometry of linear exposures, the relative speci¢c
activities of PP2C:PP1c :PP2Ac are 1:13:72.
In view of the relative selectivity of PP2Ac for PKCN the
activities of various PP2A holoenzyme forms were tested. The
heterodimer and heterotrimeric complexes can have profound
e¡ects upon PP2Ac speci¢city/activity [24^26]. As shown in
Fig. 2, none of the oligomeric forms tested showed any sig-
ni¢cant di¡erence in site selectivity for PKCN dephosphoryla-
tion. Furthermore the relative rate of dephosphorylation of
these complexes compared to PP2Ac varied by no more than
1.4-fold.
3.2. Nucleotide inhibition of PKCN dephosphorylation
The conditions providing optimum dephosphorylation of
PKCN in vitro is the TPA-induced active conformer, consis-
tent with the TPA-induced e¡ect in vivo. However, in vivo,
substrates as well as allosteric activators are present. Surpris-
ingly, inclusion of Mg-ATP in the in vitro incubation of
PKCN with PP2A completely blocked PKCN dephosphoryla-
tion (Fig. 3A). This e¡ect of Mg-ATP was not due to rephos-
Fig. 1. E¡ect of protein phosphatases against PKCN. Puri¢ed pro-
tein phosphatases were incubated with human recombinant PKCN
(500 ng) at 30‡C for the times indicated in the presence of TPA
(2 WM) and PtdSer (PS; 25 Wg). Phosphatases and concentrations
were as indicated in the panels. Reactions were stopped by addition
of SDS sample bu¡er and analysed by Western blotting for phos-
phorylation at T505, S643 and S662 and also for PKCN protein
load. A: PP1c 125 ng was used; B: PP2Ac 8 ng; C: PP2C 1000 ng;
D: quantitation showing the speci¢c activities of the three phospha-
tases indicated.
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phorylation of these sites by PKCN itself or a contaminating
kinase activity since it was also observed with Mg-ADP and
the non-hydrolysable Mg-AMPPNP. Furthermore although
unliganded ATP can inhibit PP2A [27], this was not a direct
e¡ect on PP2A itself since at these Mg2 and ATP concen-
trations no signi¢cant inhibition of PP2A phosphorylase A
phosphatase activity was observed (Fig. 3B). This potent ef-
fect of Mg-ATP in protecting PKCN from dephosphorylation
implies that in vivo either a di¡erent phosphatase activity is
involved or that a further component/event is required to
facilitate dephosphorylation.
3.3. Dephosphorylation of PKCN in NIH3T3 cells
To distinguish whether or not PP2A is responsible for the
activation-induced dephosphorylation of PKCN in vivo, we
investigated this response in intact cells. A role for PP2A
action on PKCN was consistent with the ¢nding that TPA-
induced PKCN dephosphorylation was signi¢cantly inhibited
at low concentrations of calyculin A (data not shown) or
okadaic acid as judged by immunoreactivity and reduced mi-
gration of the protein (Fig. 4A). This e¡ect was most evident
at the activation loop (T505) and autophosphorylation (S643)
sites. The hyperphosphorylated, slower migrating form of
PKCN induced by both okadaic acid (Fig. 4A) and calyculin
A (data not shown) is likely to re£ect phosphorylation at sites
other than T505, S643 and S662, since these migrate more
slowly than the initial phosphorylated protein. To assess the
one class of protein phosphatase not tested in vitro the e¡ects
of the PP2B inhibitor cyclosporin A were investigated [28]. It
was found that cyclosporin A did not e¡ect the rate of deg-
radation nor did a¡ect the migration of PKCN (Fig. 4B).
To determine more directly the potential for PP2A to ac-
count for TPA-induced PKCN dephosphorylation, association
between these two proteins was investigated. Subcon£uent
NIH3T3 cells were maintained in reduced serum overnight
and then stimulated with TPA. Lysates were prepared and
PKCN immunoprecipitated and immunoblotted for PP2Ac.
The 37 kDa catalytic subunit of PP2A was found associated
with PKCN and this was enhanced following TPA stimulation
(Fig. 4C). This association supports the notion that PP2A
plays the major role in TPA-induced PKCN dephosphoryla-
tion.
4. Discussion
The evidence presented here demonstrates that of the pro-
tein phosphatases tested, PP2Ac and complexes thereof are
the most e⁄cient in dephosphorylating PKCN in vitro. Fur-
thermore the e¡ects of inhibitors and more directly the dem-
onstration of a complex between PKCN and PP2Ac indicate
that this catalytic activity is likely to be responsible for acti-
vation-induced dephosphorylation in vivo.
All the phosphatases tested displayed similar site speci¢city
with the S643 site being the most sensitive to their action.
Given the rather di¡erent primary sequence speci¢cities exhib-
ited by these proteins in other contexts it is surmised that this
site may need to be dephosphorylated prior to the others, i.e.
that dephosphorylation is ordered. This would be consistent
Fig. 2. Dephosphorylation of PKCN by dimer and trimer forms of
PP2A in vitro. Di¡erent PP2Ac complexes (100 ng normalised to
catalytic subunit content) were incubated with human recombinant
PKCN (50 ng) at 30‡C for the times indicated in the presence of
TPA (2 mM) and PtdSer (25 mg). Reactions were stopped by addi-
tion of SDS sample bu¡er and analysed by Western blotting for
phosphorylation at T505, S643 and S662 and also for PKCN protein
load. A: PP2A (C/A) dimer. B: PP2A (C/A/B55) trimer. C: PP2A
(C/A/B72) trimer.
Fig. 3. Nucleotides prevent the dephosphorylation of PKCN by
PP2A. A: Di¡erent nucleotides (ATP, AMPPNP, ADP all at 125
WM ¢nal) and Mg2 (7.5 mM), were present in the treatment of hu-
man recombinant PKCN (500 ng) with PP2A (100 ng C/A/B55
trimer). Incubations were carried out at 30‡C for the times indicated
in the presence of TPA (2 WM) and PtdSer (25 Wg). Reactions were
stopped in SDS sample bu¡er and analysed by Western blotting for
phosphorylation at T505, S643 and S662 and also for PKCN protein
load. This is representative of several similar experiments. B: The
phosphatase activity of PP2A (2 ng C/A/B55 trimer, within the line-
ar range) against phosphorylase A was monitored in the presence or
absence of Mg2/ATP as indicated. Four independent experiments
were performed.
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with the properties of PKCK where a mutual dependency on
site occupation has been described [29,30]. The implication
here is that for PKCN the S643 is the most susceptible and
that once removed the others become ‘available’.
Activation of PKC requires the combinatorial e¡ects of al-
losteric activators and phosphorylations in the catalytic do-
main. Kinase activity is also known to be required for their
subsequent downregulation and degradation [6]. In addition
to controlling activity, phosphorylations of PKCK co-operate
to stabilise the kinase, keeping it in a phosphatase-resistant
state [29]. The work described here suggests that binding of
nucleotide can also keep PKCN in a phosphatase-resistant
state. Since the intracellular ATP concentration is relatively
high (V1 mM), the ¢nding that Mg-ATP (or related nucleo-
tides) can induce a phosphatase-resistant state for PKCN is of
particular note. In further studies it was also observed that
peptide/protein substrate binding to PKCN (histone III S,
protamine sulphate or a pseudo-substrate peptide), was su⁄-
cient to protect the kinase from dephosphorylation by PP2A
(data not shown). It is surmised that PKCN adopts a closed
phosphatase-resistant conformation upon substrate (protein/
Mg-ATP) binding. Thus, for PKCN to become dephosphory-
lated in vivo a conformational change is required; this might
be associated with a substrate release factor or through an
independently induced change in conformation.
PP2A has previously been shown to be in multi-protein
complexes with other protein kinases so that it has the ability
to dephosphorylate. This includes p70S6K and CAM kinase
IV [31,32]. These interactions, as that described here, provide
direct evidence on the action of PP2A in the inactivation of
these protein kinases. Whether these complexes are formed
with the same PP2A subunits remains to be elucidated. Whilst
it might be argued that PKCN interaction with a particular
complex of PP2Ac might by-pass the resistance to dephos-
phorylation induced by substrate, the fact that PKCN is in
part complexed to PP2A prior to activation indicates that in
fact an additional regulatory input is required for this pur-
pose.
In conclusion, the evidence here indicates that PKCN de-
phosphorylation and hence inactivation is e¡ected by PP2A
with which it forms a complex. Furthermore, this dephos-
phorylation requires an additional input in vivo to overcome
the nucleotide/substrate bound state of the kinase.
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